ImmunityBio (IBRX) News Today $2.94 -0.10 (-3.29%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period ImmunityBio: Making Its Next Strikes After Bladder Cancer ApprovalJanuary 17 at 3:02 PM | seekingalpha.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Still a Buy?ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Time to Buy?January 17 at 12:45 PM | marketbeat.comD. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX)D. Boral Capital reissued a "buy" rating and issued a $30.00 price target on shares of ImmunityBio in a research note on Thursday.January 17 at 5:50 AM | marketbeat.comTraders Purchase High Volume of Call Options on ImmunityBio (NASDAQ:IBRX)January 17 at 3:07 AM | americanbankingnews.comImmunityBio (NASDAQ:IBRX) Stock Price Down 5.2% - What's Next?ImmunityBio (NASDAQ:IBRX) Shares Down 5.2% - Should You Sell?January 16 at 5:53 PM | marketbeat.comImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: DetailsJanuary 16 at 3:03 PM | benzinga.comImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX)ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) saw unusually large options trading activity on Thursday. Stock investors acquired 8,015 call options on the stock. This represents an increase of approximately 36% compared to the typical daily volume of 5,894 call options.January 16 at 1:54 PM | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 6.3% - Here's WhyImmunityBio (NASDAQ:IBRX) Trading Up 6.3% - Time to Buy?January 16 at 1:25 PM | marketbeat.comImmunityBio stock gains 15% amid regulatory updatesJanuary 16 at 1:04 PM | msn.comImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United KingdomJanuary 15 at 5:20 PM | businesswire.comImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the AgencyJanuary 15 at 5:20 PM | businesswire.comImmunityBio (NASDAQ:IBRX) Trading Down 5.2% - What's Next?ImmunityBio (NASDAQ:IBRX) Shares Down 5.2% - Here's WhyJanuary 14, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Coverage Initiated at BTIG ResearchJanuary 12, 2025 | americanbankingnews.comImmunityBio (NASDAQ:IBRX) Sets New 12-Month Low - Here's WhyImmunityBio (NASDAQ:IBRX) Sets New 1-Year Low - Here's What HappenedJanuary 10, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Coverage Initiated by Analysts at BTIG ResearchBTIG Research assumed coverage on shares of ImmunityBio in a research note on Friday. They set a "buy" rating and a $6.00 target price on the stock.January 10, 2025 | marketbeat.comD. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX)D. Boral Capital reissued a "buy" rating and issued a $30.00 price target on shares of ImmunityBio in a research note on Monday.January 6, 2025 | marketbeat.comImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now EffectiveJanuary 6, 2025 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Trading 7% Higher - Here's What HappenedImmunityBio (NASDAQ:IBRX) Trading Up 7% - What's Next?January 3, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6% - Here's WhyImmunityBio (NASDAQ:IBRX) Trading Down 5.6% - Here's What HappenedDecember 31, 2024 | marketbeat.comImmunityBio, Inc. (NASDAQ:IBRX) Short Interest UpdateImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the target of a large drop in short interest in December. As of December 15th, there was short interest totalling 44,410,000 shares, a drop of 10.8% from the November 30th total of 49,780,000 shares. Based on an average daily trading volume, of 6,080,000 shares, the days-to-cover ratio is presently 7.3 days.December 31, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volume - Here's WhyImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volume - Here's What HappenedDecember 30, 2024 | marketbeat.comBarclays PLC Increases Position in ImmunityBio, Inc. (NASDAQ:IBRX)Barclays PLC raised its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 127.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 361,036 shares of the company's stock after purchaDecember 29, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 2.6% - Time to Buy?ImmunityBio (NASDAQ:IBRX) Stock Price Up 2.6% - Time to Buy?December 27, 2024 | marketbeat.comState Street Corp Raises Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)State Street Corp grew its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 10.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,654,460 shares of the company's stock after buying an additionDecember 22, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Sets New 1-Year Low - Time to Sell?ImmunityBio (NASDAQ:IBRX) Sets New 12-Month Low - Should You Sell?December 19, 2024 | marketbeat.comImmunityBio: Forging A New Plan After Recent $100 Million OfferingDecember 16, 2024 | seekingalpha.comImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term SuccessDecember 13, 2024 | seekingalpha.comImmunityBio (NASDAQ:IBRX) Hits New 12-Month Low - Should You Sell?ImmunityBio (NASDAQ:IBRX) Sets New 52-Week Low - What's Next?December 13, 2024 | marketbeat.comD. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingDecember 12, 2024 | investing.comD. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingDecember 12, 2024 | globenewswire.comImmunityBio's Cash Burn And Dilution Dampen Anktiva's PotentialDecember 11, 2024 | seekingalpha.comImmunityBio Shares Slide 33% After Public Offering PricesDecember 11, 2024 | marketwatch.comUS Consumer Prices Rise in Line With Expectations in November as US Equity Futures Rise Pre-BellDecember 11, 2024 | msn.comImmunityBio Shares Down on Plans for Public OfferingDecember 11, 2024 | marketwatch.comImmunityBio announces common stock offering, no amount givenDecember 11, 2024 | markets.businessinsider.comImmunityBio Prices 33.33 Mln Public Offering At $3.00 Per Share, Stock DownDecember 11, 2024 | markets.businessinsider.comImmunityBio, Inc. Announces Pricing of Public Offering of Common StockDecember 11, 2024 | businesswire.comImmunityBio, Inc. Announces Proposed Public Offering of Common StockDecember 10, 2024 | businesswire.comBiotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock MoveDecember 4, 2024 | msn.comImmunityBio (NASDAQ:IBRX) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Thursday.November 25, 2024 | marketbeat.comImmunityBio partners with nCartes to streamline trialsNovember 23, 2024 | uk.investing.comImmunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge FundsNovember 23, 2024 | msn.comImmunityBio, nCartes announce collaboration on clinical trial data fulfillmentNovember 21, 2024 | markets.businessinsider.comImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data FulfillmentNovember 21, 2024 | prnewswire.comImmunityBio announces new data from QUILT 3.032 studyNovember 20, 2024 | markets.businessinsider.comImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsNovember 19, 2024 | prnewswire.comImmunityBio Reports Third-Quarter 2024 Financial ResultsNovember 12, 2024 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Stock Price Down 5.3% - Time to Sell?ImmunityBio (NASDAQ:IBRX) Shares Down 5.3% - Here's What HappenedNovember 4, 2024 | marketbeat.comPenny Stock Trades: Joby Aviation and ImmunityBioOctober 31, 2024 | baystreet.caIMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 30, 2024 | globenewswire.com Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.380.64▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼163▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LNTH News BBIO News BPMC News LEGN News ELAN News CYTK News NUVL News GRFS News KRYS News TGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
